Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer Unsuitable for Cisplatin-Based Chemoradiation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation
J. Clin. Oncol 2023 Jan 27;[EPub Ahead of Print], VM Patil, V Noronha, N Menon, A Singh, S Ghosh-Laskar, A Budrukkar, A Bhattacharjee, M Swain, V Mathrudev, K Nawale, A Balaji, Z Peelay, M Alone, S Pathak, A Mahajan, S Kumar, N Purandare, A Agarwal, A Puranik, S Pendse, M Reddy Yallala, H Sahu, V Kapu, S Dey, J Choudhary, MR Krishna, A Shetty, N Karuvandan, R Ravind, R Rai, K Jobanputra, P Chaturvedi, PS Pai, D Chaukar, S Nair, S Thiagarajan, K PrabhashFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.